BioGeneration Ventures
Investment Details
Investor Type
Venture Capital
Asset Class Focus
Venture Capital
Stage Focus
Seed, Early Stage, Series A, Series B, Growth, Late Stage, Pre-IPO
Geographical Focus
United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Ireland, Austria, Netherlands, Hungary, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia, Romania
Industries Focus
- Healthcare
- Life Sciences
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Bioinformatics
- Biotechnology
- Medical Research
- Clinical Trials
- Regenerative Medicine
- Oncology
- Neurology
- Cardiology
- Endocrinology
- Infectious Diseases
- Immunology
- Genomics
- Stem Cell Research
- Pharmacology
- Toxicology
Investment Size:
1,500,000 to 3,000,000 USD
Investor Details Founded: 2006
BioGeneration Ventures (BGV) is a venture capital firm specializing in seed investments for innovative early-stage life sciences companies in Europe. BGV generally acts as the lead investor, focusing on biotech companies developing disruptive solutions for high unmet medical needs. The firm manages over €400 million in assets and has a strong track record of significant financial returns through its investments in healthcare innovations and providing the expertise to build world-class companies.
BGV's investment strategy is to seek innovations with a truly differentiated scientific foundation, supported by convincing experimental data. The firm aims to build new companies around either single assets or technology platforms, with the goal of creating transformational new medicines and generating significant returns for its investors. BGV's portfolio includes companies such as Acerta Pharma, which was acquired by AstraZeneca for up to $7 billion in 2016, and whose lead product, Calquence®, is now approved and marketed in the US. Other portfolio companies include Catalym, Kivu Bioscience, and Mironid.
BGV is based in Naarden, the Netherlands, and collaborates closely with Forbion, a leading European life sciences venture capital fund with €3 billion in capital under management. The firm is a signatory to the United Nations Principles for Responsible Investment (PRI) and focuses on addressing high and unmet medical needs to improve the quality of patients' lives. BGV assesses the impact of its investments on patients and society using a scoring mechanism and integrates disclosures on sustainability risks, principle adverse impacts, and remuneration policy in accordance with the Regulation (EU) 2019/2088 (SFDR) in its Policy for Responsible Investments.
Requirements
- Innovative life sciences companies with a differentiated scientific foundation
- Strong management teams
- Potential for significant healthcare impact
- Companies addressing high unmet medical needs
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
[Contact Number Hidden]
Portfolio Companies
- Acerta Pharma
- CatalYm
- KIVU BIOSCIENCE
- Mironid
Mentioned In
-
$19.95
-
$24.95
-
$19.95
-
$49.95
-
$39.95
-
$99.00
-
$245.00
Claim this Investor
Are you an official representative of BioGeneration Ventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim